Alice Hui Li Bong

Alice Hui Li Bong is a Postdoctoral Research Fellow at the School of Pharmacy and Pharmaceutical Sciences, The University of Queensland, where she investigates calcium signaling mechanisms in breast cancer pathogenesis and therapeutic resistance. Her work bridges molecular oncology and pharmacology to identify novel targets for breast cancer treatment.

Her primary research interests include:

• Breast Cancer
• Calcium Signaling
• Molecular Oncology
• Pharmacology
• Cancer Cell Biology

Dr. Bong's research program focuses on how calcium-regulating proteins (ORAI1, STIM1, TMCO1, NCS-1) influence breast cancer cell behavior, particularly in basal subtypes. She employs advanced techniques including genetically encoded calcium indicators (GCaMP6m) for real-time imaging of cytosolic calcium dynamics during chemotherapeutic interventions. Her work reveals critical mechanisms of drug resistance involving calcium-dependent apoptosis pathways and transcriptional regulation.

Analysis of her 10 journal publications (2017-2024) shows consistent progression in understanding calcium signaling's role in breast cancer. Early work established foundational links between calcium channels and doxorubicin response, while recent studies (2022-2024) demonstrate sophisticated mechanistic insights into ORAI1/TMCO1 functions in gene regulation and apoptotic resistance. Her research increasingly integrates tumor microenvironment perspectives, as evidenced by 2023-2024 conference presentations on calcium signaling in breast cancer stroma.

Dr. Bong completed her PhD at The University of Queensland in 2019 with the thesis "Calcium channels, pumps and sensors as modulators of therapeutic response in basal breast cancer". She actively disseminates findings through major international forums including the American Association for Cancer Research (AACR) Annual Meeting and ASCEPT conferences, demonstrating strong engagement with the global oncology research community.